Hypertension Clinical Trial
— NMSOfficial title:
Understanding and Appraising the New Medicine Service in England
About 25% medicines prescribed for long term conditions are not taken as directed, and
approximately 15% people receiving a new medicine take few, if any, doses. The New Medicine
Service (NMS) is a community pharmacy service that started in England in October 2011 which
involves the pharmacist providing additional support to patients starting a new medicine for
some breathing problems (asthma & COPD), high blood pressure, adult onset diabetes or
medicines which reduce blood clotting. It aims to improve the way patients take their
medicines improving outcomes and reducing costs to the National Health Service (NHS).
The investigators will assess the effectiveness and cost effectiveness of the NMS using a
research study where some people will receive the NMS, and some won't, so The investigators
can look at the effect of the NMS on problems with their medicines, medicines taking and use
of the NHS in general. Data will be collected in the East Midlands, South Yorkshire and
London areas.
The investigators will recruit 500 patients from a range of different pharmacies and follow
them up at six, ten and twenty six weeks after starting their new medicine to assess effects
on medicines taking behaviour, patients' reported problems with medicines, referrals to
their General Practitioner (GP) and use of NHS resources. The investigators will compare the
data gathered from this study with that being collected routinely by all pharmacies in
England to provide wider estimates of cost effectiveness.
The investigators will also explore how the NMS service is being implemented by pharmacies.
A sample of patients from the main study will be followed in more detail. This will involve
recording the consultations with the pharmacist and also interviewing patients about their
experience of the service. The investigators will interview the patients GP to investigate
their views of the service. The investigators will also try to understand why people decline
the invitation for the NMS
| Status | Completed |
| Enrollment | 504 |
| Est. completion date | April 2014 |
| Est. primary completion date | April 2014 |
| Accepts healthy volunteers | No |
| Gender | Both |
| Age group | 14 Years and older |
| Eligibility |
Inclusion Criteria: - Community dwelling patients eligible for NMS (aged from 14 years starting a new medicine for asthma/COPD, diabetes (Type 2), antiplatelet/anticoagulation or hypertension). Exclusion Criteria: - Patients collecting a repeat prescription for a medicine (i.e. not new) for asthma/COPD, type 2 diabetes mellitus (T2DM), antiplatelets/anticoagulants or hypertension - Patients collecting a medicine where the only change from the previous medicine involves a dosage or formulation change only - Participants who are unable to understand patient/participant study documents - Participants who are unable and unwilling to provide written consent / assent |
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care
| Country | Name | City | State |
|---|---|---|---|
| United Kingdom | Doncaster PCT | Doncaster | South Yorkshire |
| United Kingdom | Cambden, Barnet, Islington PCTs | London | |
| United Kingdom | Nottingham City PCT/Nottingham City Care | Nottingham | |
| United Kingdom | Nottinghamshire County PCT/ County Health Partnerships | Nottingham | Notts |
| Lead Sponsor | Collaborator |
|---|---|
| University of Nottingham | Department of Health, United Kingdom, University College, London, University of Warwick |
United Kingdom,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Medicines adherence | Patients will report medicines adherence using the service specified adherence question and against standard adherence scales | Change in adherence from 6 weeks to 10 weeks and 26 weeks | No |
| Primary | Cost effectiveness | Patients will record all NHS resource use during the study period via a self completion diary to assess the impact on cost effectiveness up to 6 months post initiation. | 6 months | No |
| Primary | Operation of the NMS | The investigators will qualitatively describe the operation of the NMS, the complexity and nature of resulting consultations in terms of patient engagement, advice-giving and support. Additionally it will determine acceptability to stakeholders, reasons for success or lack of success, feasibility within the service delivery environment and generalisability and replicability across disease indications and community pharmacy settings | 1 year from first recruited patient | No |
| Secondary | Patients' understanding of their medicines | The investigators will qualitatively evaluate patients' understanding of their medicines and the extent to which they are informed and supported in their medicines-related behaviour. | 10 weeks | No |
| Secondary | Pharmacovigilance | The investigators will qualitatively determine whether NMS encourages improved pharmacovigilance by community pharmacists and patients. | 1 year from first recruited patient | No |
| Secondary | Stakeholder experience | The investigators will qualitatively characterise patient (and/or carer) and professional experience. | 1 year from first recruited patient | No |
| Secondary | Professional relationships | The investigators will qualitatively explore inter-professional and patient-professional relationships. | 1 year from first recruited patient | No |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT04591808 -
Efficacy and Safety of Atorvastatin + Perindopril Fixed-Dose Combination S05167 in Adult Patients With Arterial Hypertension and Dyslipidemia
|
Phase 3 | |
| Recruiting |
NCT04515303 -
Digital Intervention Participation in DASH
|
||
| Completed |
NCT05433233 -
Effects of Lifestyle Walking on Blood Pressure in Older Adults With Hypertension
|
N/A | |
| Completed |
NCT05491642 -
A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses
|
Phase 1 | |
| Completed |
NCT03093532 -
A Hypertension Emergency Department Intervention Aimed at Decreasing Disparities
|
N/A | |
| Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
| Completed |
NCT05529147 -
The Effects of Medication Induced Blood Pressure Reduction on Cerebral Hemodynamics in Hypertensive Frail Elderly
|
||
| Recruiting |
NCT05976230 -
Special Drug Use Surveillance of Entresto Tablets (Hypertension)
|
||
| Recruiting |
NCT06363097 -
Urinary Uromodulin, Dietary Sodium Intake and Ambulatory Blood Pressure in Patients With Chronic Kidney Disease
|
||
| Completed |
NCT06008015 -
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1015" and Co-administration of "BR1015-1" and "BR1015-2" Under Fed Conditions in Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT05387174 -
Nursing Intervention in Two Risk Factors of the Metabolic Syndrome and Quality of Life in the Climacteric Period
|
N/A | |
| Completed |
NCT04082585 -
Total Health Improvement Program Research Project
|
||
| Recruiting |
NCT05121337 -
Groceries for Black Residents of Boston to Stop Hypertension Among Adults Without Treated Hypertension
|
N/A | |
| Withdrawn |
NCT04922424 -
Mechanisms and Interventions to Address Cardiovascular Risk of Gender-affirming Hormone Therapy in Trans Men
|
Phase 1 | |
| Active, not recruiting |
NCT05062161 -
Sleep Duration and Blood Pressure During Sleep
|
N/A | |
| Completed |
NCT05087290 -
LOnger-term Effects of COVID-19 INfection on Blood Vessels And Blood pRessure (LOCHINVAR)
|
||
| Not yet recruiting |
NCT05038774 -
Educational Intervention for Hypertension Management
|
N/A | |
| Completed |
NCT05621694 -
Exploring Oxytocin Response to Meditative Movement
|
N/A | |
| Completed |
NCT05688917 -
Green Coffee Effect on Metabolic Syndrome
|
N/A | |
| Recruiting |
NCT05575453 -
OPTIMA-BP: Empowering PaTients in MAnaging Blood Pressure
|
N/A |